Please use this identifier to cite or link to this item:
Title: Pembrolizumab in relapsed or refractory Richter syndrome.
Austin Authors: Armand, Philippe;Murawski, Niels;Molin, Daniel;Zain, Jasmine;Eichhorst, Barbara;Gulbas, Zafer;Hawkes, Eliza A ;Pagel, John M;Phillips, Tycel;Ribrag, Vincent;Svoboda, Jakub;Stathis, Anastasios;Chatterjee, Arkendu;Orlowski, Robert;Marinello, Patricia;Christian, Beth
Affiliation: Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Dana-Farber Cancer Institute, Boston, MA, USA
Merck & Co., Inc, Kenilworth, NJ, USA
City of Hope, Duarte, CA, USA
Swedish Center for Blood Disorders and Stem Cell Transplants, Swedish Cancer Institute, Seattle, WA, USA
University of Cologne, Cologne, Germany
Rogel Cancer Center, Ann Arbor, MI, USA
The James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, USA
Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA
Anadolu Medical Center, Istanbul, Turkey
Universit├Ąts-klinikum des Saarlandes Innere Medizin I, Homburg, Germany
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden..
Institut Gustave Roussy, Villejuif, France
Issue Date: 16-Jun-2020 2020-07
Publication information: British Journal of Haematology 2020; 190(2): e117-e120
DOI: 10.1111/bjh.16762
ORCID: 0000-0001-6098-1603
PubMed URL: 32544980
Type: Journal Article
Subjects: PD-1
Richter syndrome
chronic lymphocytic leukaemia
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.